|
|
|
|
|
|
Sponsors and Collaborators: |
University of Kansas Novartis Kansas Masonic Cancer Research Institute |
Information provided by: | University of Kansas |
ClinicalTrials.gov Identifier: | NCT00222144 |
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.
Condition | Intervention | Phase |
Lung Cancer |
Drug: Gleevec and Taxotere |
Phase II |
MedlinePlus related topics: | Cancer Lung Cancer |
ChemIDplus related topics: | Docetaxel Imatinib Imatinib mesylate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer |
Estimated Enrollment: | 32 |
Study Start Date: | February 2006 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
Gleevec and Taxotere
|
Drug: Gleevec and Taxotere
Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
|
The purpose of this study is to evaluate the response rate of Gleevec with Taxotere in patients with recurrent non-small cell lung cancer. Also to determine the expression of PDGF-R, phosphorylated PDGF-r and C-kit in the original tissue and correlate with response. If the patient has a tumor in an accessible location, we will ask for consent from the patient to obtain biopsy before and after the therapy to assess the same molecular markers.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Kansas | |||||
University of Kansas Medical Center | |||||
Kansas City, Kansas, United States, 66160 | |||||
United States, Missouri | |||||
Kansas City VA Medical Center | |||||
Kansas City, Missouri, United States, 64128 |
University of Kansas |
Novartis |
Kansas Masonic Cancer Research Institute |
Principal Investigator: | Chao H Huang, MD | University of Kansas |
Responsible Party: | University of Kansas Medical Center ( Chao H Huang, MD ) |
Study ID Numbers: | 9698 |
First Received: | September 13, 2005 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00222144 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|